Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.69 |
| ▸ | PDE4A | P27815 | 10/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.69 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL537141 | 1.00 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15862397 | 1.00 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15869360 | 1.00 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537296 | 1.00 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL15869365 | 1.00 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL14924750 | 0.93 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3554030 | 0.91 | PDE4B (0.59) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3550822 | 0.91 | PDE4B (0.60) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL2966977 | 0.90 | PDE4B (0.56) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL3113890 | 0.89 | PDE4B (0.58) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45685-E1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2015-09-29 | — | — | US | disclosed |
| EP-1228071-B8 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2255801-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2263669-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2012-02-08 | — | — | EP | disclosed |
| US-8030343-B2 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2011-10-04 | — | — | US | disclosed |
| EP-1698334-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2263669-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2255801-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2010-12-01 | — | — | EP | disclosed |
| US-7678825-B2 | Pharmaceutically active isoindoline derivates | CELGENE CORPORATION (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION | 2008-09-11 | — | — | US | disclosed |
| EP-1228071-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1698334-A1 | Pharmaceutically active isoindoline derivatives | CELGENE CORPORATION (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | MAN HON-WAH | 2004-07-29 | — | — | US | disclosed |
| US-6667316-B1 | Amido or imido functionality; tumor necrosis factor alpha, phosphodiesterases, matrix metalloproteases and angiogenesis inhibitors | CELGENE CORPORATION | 2003-12-23 | — | — | US | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221196-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | PDE3A, PDE2A, PDE5A | PDE4B 10/4885PDE4C 8/4885PDE4A 6/4885 |
| US-20040147588-A1 | Pharmaceutically active isoindoline derivatives | PDE3A, PDE5A, PDE2A | PDE4B 14/4885PDE4C 10/4885PDE4A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.